Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neuroendocrine tumor of the duodenum/pancreas by histology or bone scan~* Functional or nonfunctional tumor~  * Tumor meets ≥ 1 of the following criteria:~    * Hepatic or extrahepatic metastases~   * Progressive locally advanced tumor (primary or adenopathies)~* Unresectable disease~* Tumor differentiated and meets the following criteria:~  * Ki 67 ≤ 15%~ * Less than 10 mitoses per 10 large fields~* Measurable or evaluable disease~  * Target lesions must meet 1 of the following criteria within the past 6 months:~    * Increase of 20% in the longest diameter~   * New metastases detected~ * Minimum size of lesions must be 1 of the following:~    * More than 15 mm for metastases~   * More than 50 mm for primary tumor or local lymph nodes~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Creatinine ≤ 1.5 mg/dL~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.8 mg/dL~* No coronary insufficiency or symptomatic cardiac disease~* No intestinal obstruction, enteropathy, or uncontrolled chronic diarrhea~* No Gilbert's disease~* No psychological, social, familial, or geographic condition that would preclude study treatment~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after completion of study therapy~* No other condition that would preclude study therapy~PRIOR CONCURRENT THERAPY:~* No prior adjuvant radiotherapy~* At least 3 months since prior interferon~* Prior somatostatin analogs or antisecretories allowed~* No other prior treatment for this cancer~* No concurrent radiotherapy to the target lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FOLFIRI (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).